Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium

作者：Dixon Suzanne C; Nagle Christina M; Wentzensen Nicolas; Trabert Britton; Beeghly Fadiel Alicia; Schildkraut Joellen M; Moysich Kirsten B; deFazio Anna; Risch Harvey A; Rossing Mary Anne; Doherty Jennifer A; Wicklund Kristine G; Goodman Marc T; Modugno Francesmary; Ness Roberta B; Edwards Robert P; Jensen Allan; Kjaer Susanne K; Hogdall Estrid; Berchuck Andrew; Cramer Daniel W; Terry Kathryn L; Poole Elizabeth M; Bandera Elisa V; Paddock Lisa E

来源：British Journal of Cancer, 2017, 116(9): 1223-1228.

DOI：10.1038/bjc.2017.68

• ovarian cancer
• aspirin
• nonsteroidal anti-inflammatory drugs
• NSAID
• paracetamol
• acetaminophen
• pooled analysis
• survival

Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with improved survival in some cancers, but evidence for ovarian cancer is limited.
Methods: Pooling individual-level data from 12 Ovarian Cancer Association Consortium studies, we evaluated the association between self-reported, pre-diagnosis use of common analgesics and overall/progression-free/disease-specific survival among 7694 women with invasive epithelial ovarian cancer (4273 deaths).
Results: Regular analgesic use (at least once per week) was not associated with overall survival (pooled hazard ratios, pHRs (95% confidence intervals): aspirin 0.96 (0.88-1.04); non-aspirin NSAIDs 0.97 (0.89-1.05); acetaminophen 1.01 (0.93-1.10)), nor with progression-free/disease-specific survival. There was however a survival advantage for users of any NSAIDs in studies clearly defining non-use as less than once per week (pHR=0.89 (0.82-0.98)).
Conclusions: Although this study did not show a clear association between analgesic use and ovarian cancer survival, further investigation with clearer definitions of use and information about post-diagnosis use is warranted.

• 出版日期2017-4
• 单位河北医科大学